Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease

Translational Research

Volumn 166, Issue 6, 2015, Pages 783-787

  Romero, Atocha ^a   Acosta Eyzaguirre, Daniel ^b   Sanz, Julián ^c   Moreno, Fernando ^a   Serrano, Gloria ^a   Diáz Rubio, Eduardo ^a   Caldés, Trinidad ^a   Garcia Saenz, José Á ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b Facultad HM Hospitales de Ciencias de la Salud de la UCJC   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING FREE DNA; DNA; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; UNCLASSIFIED DRUG; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL POLYMERASE CHAIN REACTION; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDICAL HISTORY; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR VOLUME; BLOOD; BREAST TUMOR; GENETICS; METASTASIS; MUTATION; PATHOLOGY; PROCEDURES;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; MUTATION; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION;

EID: 84960472019     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.04.010     Document Type: Article

References (25)

1. K. Stemke-Hale, A.M. Gonzalez-Angulo, A. Lluch, and et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer Cancer Res 68 2008 6084 6091
2. S. Banerji, K. Cibulskis, C. Rangel-Escareno, and et al. Sequence analysis of mutations and translocations across breast cancer subtypes Nature 486 2012 405 409
3. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
4. I.G. Campbell, S.E. Russell, D.Y. Choong, and et al. Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Res 64 2004 7678 7681
5. K. Kalinsky, L.M. Jacks, A. Heguy, and et al. PIK3CA mutation associates with improved outcome in breast cancer Clin Cancer Res 15 2009 5049 5059
6. S.Y. Li, M. Rong, F. Grieu, and B. Iacopetta PIK3CA mutations in breast cancer are associated with poor outcome Breast Cancer Res Treat 96 2006 91 95
7. S. Loi, S. Michiels, D. Lambrechts, and et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer J Natl Cancer Inst 105 2013 960 967
8. S. Loibl, G. von Minckwitz, A. Schneeweiss, and et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer J Clin Oncol 32 2014 3212 3220
9. J. Baselga, J. Cortés, S.A. Im, and et al. Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer J Clin Oncol 32 2014 3753 3761
10. G.N. Hortobagyi, M.J. Piccart, H.S. Rugo, and et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. 2013 ASCO Annual Meeting J Clin Oncol 31 2013 (suppl; Abstract LBA509)
11. E. Amir, N. Miller, W. Geddie, and et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer J Clin Oncol 30 2012 587 592
12. S.J. Dawson, D.W. Tsui, M. Murtaza, and et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer N Engl J Med 368 2013 1199 1209
13. J.A. Beaver, D. Jelovac, S. Balukrishna, and et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer Clin Cancer Res 20 2014 2643 2650
14. M.J. Higgins, D. Jelovac, E. Barnathan, and et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood Clin Cancer Res 18 2012 3462 3469
15. R.E. Board, A.M. Wardley, J.M. Dixon, and et al. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer Breast Cancer Res Treat 120 2010 461 467
16. M.J. Brennan, W.L. Donegan, and D.E. Appleby The variability of estrogen receptors in metastatic breast cancer Am J Surg 137 1979 260 262
17. I.M. Holdaway, and J.V. Bowditch Variation in receptor status between primary and metastatic breast cancer Cancer 52 1983 479 485
18. L. Pusztai, G. Viale, C.M. Kelly, and C.A. Hudis Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis Oncologist 15 2010 1164 1168
19. J. Dupont Jensen, A.V. Laenkholm, A. Knoop, and et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer Clin Cancer Res 17 2011 667 677
20. E.B. Schleifman, R. Desai, J.M. Spoerke, and et al. Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers PLoS One 9 2014 e88401
21. L.M. Arthur, A.K. Turnbull, L. Renshaw, and et al. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer Breast Cancer Res Treat 147 2014 211 219
22. V.S. Sabine, C. Crozier, C.L. Brookes, and et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study J Clin Oncol 32 2014 2951 2958
23. R.J. Crowder, C. Phommaly, Y. Tao, and et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer Cancer Res 69 2009 3955 3962
24. T. Bachelot, C. Bourgier, C. Cropet, and et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study J Clin Oncol 30 2012 2718 2724
25. J. Baselga, M. Campone, M. Piccart, and et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529